Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats.
Animals
Blood Glucose
/ metabolism
Canagliflozin
/ therapeutic use
Cell Count
Diabetes Mellitus, Type 2
/ drug therapy
Diabetic Neuropathies
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Drug Therapy, Combination
Glycated Hemoglobin
/ analysis
Hypoglycemic Agents
/ therapeutic use
Insulin-Secreting Cells
/ pathology
Islets of Langerhans
/ pathology
Male
Pancreas
/ pathology
Parasympathetic Nervous System
/ pathology
Pyrazoles
/ therapeutic use
Rats
Rats, Wistar
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Thiazolidines
/ therapeutic use
Combination therapy
DPP4 inhibitor
Parasympathetic innervation
SGLT2 inhibitor
Type 2 diabetes
β-Cell
Journal
Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
14
02
2020
revised:
04
04
2020
accepted:
13
04
2020
pubmed:
18
4
2020
medline:
4
8
2020
entrez:
18
4
2020
Statut:
ppublish
Résumé
Parasympathetic nerve (PN) signaling plays a crucial role in the maintenance of pancreatic β-cell volume density (V We divided 5-week old male GK and Wistar rats (W) into a DPP4i-treated group (GKTe), SGLT2i-treated group (GKCa), and combination-treated group (GKCaTe). After 25 weeks, the pancreata was pathologically evaluated. V The combination therapy of DPP4i and SGLT2i improved V
Identifiants
pubmed: 32302619
pii: S0026-0495(20)30096-2
doi: 10.1016/j.metabol.2020.154232
pii:
doi:
Substances chimiques
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
0
Blood Glucose
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Pyrazoles
0
Sodium-Glucose Transporter 2 Inhibitors
0
Thiazolidines
0
Canagliflozin
0SAC974Z85
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154232Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest There is no potential conflict of interest for all authors except for HM. Teneligliptin and canagliflozin were kindly gifted from Tanabe Mitsubishi Pharmacological Inc. Research grant was given to HM by Tanabe Mitsubishi Pharmacological Inc, Japan.